This preprint is under consideration at Journal of Cardiothoracic Surgery. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
yingmin lu
xinhua (chongming) hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background：Drug-coated balloon (DCB) is a new technology that has emerged in recent years, and it has been proven to be effective and safe in the treatment of restenosis in the stent. The purpose of this article is to observe the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. Methods: A total of 80 patients who were admitted to our department due to STEMI from January 2018 to December 2019 were selected. The subjects were randomly divided into drug-coated balloon treatment group (balloon group, n=38) and drug-eluting stent (DES) treatment group (stent group, n=42). The patients were followed up for 1 year to understand the incidence of major adverse cardiovascular events (MACEs) at 1 month, 6 months and 1 year after operation. Coronary angiography was reexamined at 1 year after operation to understand the late lumen loss (LLL) of the two groups.
Results: At the 1-year follow-up, the target lesion LLL in the balloon group was (−0.12±0.46) mm, while the target lesion in the stent group was (0.14±0.37) mm (P<0.05). Within 1 year, the incidence of MACEs in the balloon group was 11%, and the incidence of MACEs in the stent group was 12%. There was no significant difference between the two groups.
Conclusion: DCB therapy alone is safe and effective when PCI is performed for STEMI, and it shows good clinical results during the 1-year follow-up period.
Keywords
drug-coated balloon, acute ST-segment elevation myocardial infarction, late lumen loss
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 05 May, 2021
Editor assigned
On 29 Apr, 2021
Submission checks complete
On 29 Apr, 2021
Editor invited
On 29 Apr, 2021
This version was not preprinted
Version 1
Posted 23 Feb, 2021
No community comments so far
Editorial decision: Major revision
On 05 Apr, 2021
Review #1 received
Received 18 Mar, 2021
Review #2 received
Received 16 Mar, 2021
Reviewer #2 agreed
On 04 Mar, 2021
Reviewer #3 agreed
On 04 Mar, 2021
Reviewer #1 agreed
On 04 Mar, 2021
Reviewers invited
Invitations sent on 04 Mar, 2021
Reviews received
Received 04 Mar, 2021
Editor assigned
On 10 Feb, 2021
Submission checks complete
On 10 Feb, 2021
Editor invited
On 10 Feb, 2021
First submitted
On 08 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cardiothoracic Surgery
Learn more about our company.
This preprint is under consideration at Journal of Cardiothoracic Surgery. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
yingmin lu
xinhua (chongming) hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 05 May, 2021
Editor assigned
On 29 Apr, 2021
Submission checks complete
On 29 Apr, 2021
Editor invited
On 29 Apr, 2021
This version was not preprinted
Version 1
Posted 23 Feb, 2021
No community comments so far
Editorial decision: Major revision
On 05 Apr, 2021
Review #1 received
Received 18 Mar, 2021
Review #2 received
Received 16 Mar, 2021
Reviewer #2 agreed
On 04 Mar, 2021
Reviewer #3 agreed
On 04 Mar, 2021
Reviewer #1 agreed
On 04 Mar, 2021
Reviewers invited
Invitations sent on 04 Mar, 2021
Reviews received
Received 04 Mar, 2021
Editor assigned
On 10 Feb, 2021
Submission checks complete
On 10 Feb, 2021
Editor invited
On 10 Feb, 2021
First submitted
On 08 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cardiothoracic Surgery
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background：Drug-coated balloon (DCB) is a new technology that has emerged in recent years, and it has been proven to be effective and safe in the treatment of restenosis in the stent. The purpose of this article is to observe the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. Methods: A total of 80 patients who were admitted to our department due to STEMI from January 2018 to December 2019 were selected. The subjects were randomly divided into drug-coated balloon treatment group (balloon group, n=38) and drug-eluting stent (DES) treatment group (stent group, n=42). The patients were followed up for 1 year to understand the incidence of major adverse cardiovascular events (MACEs) at 1 month, 6 months and 1 year after operation. Coronary angiography was reexamined at 1 year after operation to understand the late lumen loss (LLL) of the two groups.
Results: At the 1-year follow-up, the target lesion LLL in the balloon group was (−0.12±0.46) mm, while the target lesion in the stent group was (0.14±0.37) mm (P<0.05). Within 1 year, the incidence of MACEs in the balloon group was 11%, and the incidence of MACEs in the stent group was 12%. There was no significant difference between the two groups.
Conclusion: DCB therapy alone is safe and effective when PCI is performed for STEMI, and it shows good clinical results during the 1-year follow-up period.
Loading...